Hangzhou Coco Healthcare Products Co.,Ltd. (SHE:301009)
China · Delayed Price · Currency is CNY 8.47
-0.39 (-4.40%)
Sep 15, 2026, 3:00 PM CST
SHE:301009 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,185 | 1,131 | 1,058 | 1,054 | 1,166 | 1,170 |
Other Revenue | - | 19.7 | 20.28 | 27.55 | 20.24 | 16.19 |
| 1,185 | 1,150 | 1,079 | 1,081 | 1,186 | 1,186 | |
Revenue Growth | 7.06% | 6.65% | -0.27% | -8.83% | -0.01% | -27.44% |
Cost of Revenue | 903.95 | 885.19 | 866.7 | 900.27 | 1,043 | 973.16 |
Gross Profit | 280.81 | 265.04 | 211.84 | 181.22 | 143.63 | 213.25 |
Selling, General & Admin | 210.17 | 194.25 | 165.35 | 135.44 | 125.51 | 127.85 |
Research & Development | 51.09 | 48.36 | 45.04 | 44.11 | 50.98 | 49.27 |
Other Operating Expenses | -0.76 | 0.77 | -1.27 | 1.18 | 3.13 | 4.26 |
Operating Expenses | 260.51 | 242.67 | 209.96 | 177.24 | 184.84 | 179.32 |
Operating Income | 20.31 | 22.37 | 1.88 | 3.97 | -41.21 | 33.92 |
Interest Expense | - | -2.26 | -0.73 | -0.65 | -0.28 | -0.96 |
Interest & Investment Income | 8.26 | 31.29 | 20.72 | 24.25 | 23.58 | 17.7 |
Currency Exchange Gain (Loss) | - | -14.44 | 8.72 | 5.66 | 16.54 | -4.37 |
Other Non Operating Income (Expenses) | -19.3 | -1 | -3.18 | -1.56 | -1.22 | -5.63 |
EBT Excluding Unusual Items | 9.27 | 35.95 | 27.42 | 31.67 | -2.59 | 40.66 |
Gain (Loss) on Sale of Investments | 0.89 | 0.92 | -0.38 | -3.34 | - | - |
Gain (Loss) on Sale of Assets | -0.1 | -0.1 | -0.04 | -0.1 | 0.12 | 0.04 |
Asset Writedown | -12.96 | -0.01 | -0.21 | -14.09 | -62.3 | -0.16 |
Other Unusual Items | - | 2.59 | 6.11 | 5.32 | 8.39 | 2.99 |
Pretax Income | -2.9 | 39.35 | 32.91 | 19.45 | -56.37 | 43.53 |
Income Tax Expense | -5.02 | 2.08 | 2.34 | 1.69 | -0.13 | 4.09 |
Earnings From Continuing Operations | 2.12 | 37.27 | 30.57 | 17.76 | -56.25 | 39.44 |
Minority Interest in Earnings | -2.19 | -1.15 | 0.61 | 2.42 | 13.12 | 0.31 |
Net Income | -0.07 | 36.12 | 31.17 | 20.18 | -43.13 | 39.75 |
Net Income to Common | -0.07 | 36.12 | 31.17 | 20.18 | -43.13 | 39.75 |
Net Income Growth | - | 15.87% | 54.44% | - | - | -81.43% |
Shares Outstanding (Basic) | 261 | 258 | 260 | 288 | 270 | 234 |
Shares Outstanding (Diluted) | 261 | 258 | 260 | 288 | 270 | 234 |
Shares Change | 1.05% | -0.69% | -9.91% | 6.98% | 15.29% | 14.71% |
EPS (Basic) | -0.00 | 0.14 | 0.12 | 0.07 | -0.16 | 0.17 |
EPS (Diluted) | -0.00 | 0.14 | 0.12 | 0.07 | -0.16 | 0.17 |
EPS Growth | - | 16.67% | 71.43% | - | - | -83.81% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 38.89 | 86.88 | -22.91 | 161.69 | -153.6 | -189.92 |
Free Cash Flow Per Share | 0.15 | 0.34 | -0.09 | 0.56 | -0.57 | -0.81 |
Dividend Per Share | 0.120 | 0.120 | 0.070 | 0.075 | - | 0.070 |
Dividend Growth | - | 71.43% | -6.67% | - | - | - |
Gross Margin | 23.70% | 23.04% | 19.64% | 16.76% | 12.11% | 17.97% |
Operating Margin | 1.71% | 1.94% | 0.18% | 0.37% | -3.47% | 2.86% |
Profit Margin | -0.01% | 3.14% | 2.89% | 1.87% | -3.64% | 3.35% |
Free Cash Flow Margin | 3.28% | 7.55% | -2.12% | 14.95% | -12.95% | -16.01% |
EBITDA | 79.46 | 80.28 | 56.75 | 57.7 | 18.53 | 82.5 |
EBITDA Margin | 6.71% | 6.98% | 5.26% | 5.33% | 1.56% | 6.95% |
D&A For EBITDA | 59.16 | 57.91 | 54.86 | 53.72 | 59.74 | 48.57 |
EBIT | 20.31 | 22.37 | 1.88 | 3.97 | -41.21 | 33.92 |
EBIT Margin | 1.71% | 1.94% | 0.17% | 0.37% | -3.47% | 2.86% |
Effective Tax Rate | - | 5.29% | 7.11% | 8.69% | - | 9.40% |
Revenue as Reported | - | 1,150 | 1,079 | 1,081 | 1,186 | 1,186 |